Growing product sales and an expanding pipeline led Genzyme Corp. to report solid earnings for the second quarter, once again beating consensus estimates. (BioWorld Today)
Growing product sales and an expanding pipeline led Genzyme Corp. to report solid earnings for the second quarter, once again beating consensus estimates. (BioWorld Today)
Immune Control Inc. raised $11.3 million in its Series A financing to develop serotonin antagonists for lymphocytic cancers and autoimmune diseases, and to begin the first two clinical programs in multiple myeloma and psoriasis. (BioWorld Today)
Immune Control Inc. raised $11.3 million in its Series A financing to develop serotonin antagonists for lymphocytic cancers and autoimmune diseases, and to begin the first two clinical programs in multiple myeloma and psoriasis. (BioWorld Today)
Four months after reporting positive results from a Phase IIb trial of its endothelin A receptor antagonist, SPP301, in diabetic nephropathy, Speedel Group AG initiated a pivotal Phase III study in Type II diabetes patients. (BioWorld International)
